Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
321 to 340 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| R01AR075015 | Epidermal Gene Regulation by Transcription Elongation and Termination | 1 | 2024 |
| R01AT011326 | Development of a platform for spatial functional genomics | 1 | 2024 |
| R01CA075115 | Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression | 1 | 2024 |
| R01CA116021 | New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors | 1 | 2024 |
| R01CA128943 | Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer | 1 | 2024 |
| R01CA138804 | Role of PALB2 in the DNA Damage Response and Cancer Suppression | 1 | 2024 |
| R01CA161870 | The Genetics of Ocular Melanoma | 1 | 2024 |
| R01CA166440 | Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF | 1 | 2024 |
| R01CA228457 | Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition | 1 | 2024 |
| R01CA231349 | Developing Novel Therapeutic Approaches Targeting Macrophages in GBM | 1 | 2024 |
| R01CA237536 | Non-Canonical Phosphatidylinositol Kinases in Triple Negative Breast Cancer | 1 | 2024 |
| R01CA238237 | Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma | 1 | 2024 |
| R01CA241191 | Inhibition of Bcl-xL by Targeted Degradation | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA242845 | Blocking tumor progression in therapy-responsive RET aberration-associated cancer | 1 | 2024 |
| R01CA244254 | Development of ASH1L inhibitors for acute leukemia | 1 | 2024 |
| R01CA244341 | Characterization and targeting of rapid nucleotide exchange RAS mutations | 1 | 2024 |
| R01CA244660 | Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling | 1 | 2024 |
| R01CA246653 | Mouse models of Kras-mutant colorectal cancer | 1 | 2024 |
| R01CA250102 | Melanoma: Metabolic Biomarkers of Response to Targeted Therapy | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=17